Overview

A Phase 2, Open Label, PK Study of TLC599 in Subject With Osteoarthritis of the Knee

Status:
Recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
This study is a Phase 2, open-label, 1-period, parallel study with 9 cohorts of subjects with OA of the knee enrolled to receive single-dose of TLC599 or DSP via IA injection.
Phase:
Phase 2
Details
Lead Sponsor:
Taiwan Liposome Company
Treatments:
BB 1101
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate